back to cluster viewer
cluster path 001111101000001
125 words, 6,709 tokens
freq alpha suffix
Words in frequency order
1 | survivors | 4,217
|
2 | chemoprevention | 837
|
3 | victims | 653
|
4 | sufferers | 327
|
5 | survivorship | 267
|
6 | perpetrators | 66
|
7 | therapy-general | 33
|
8 | therapy-breast | 23
|
9 | epidemiol | 19
|
10 | microspores | 19
|
11 | therapy-lung | 12
|
12 | recidivists | 11
|
13 | therapy-prostate | 11
|
14 | antigen-125 | 10
|
15 | defenders | 9
|
16 | subpanel | 8
|
17 | non-withdrawers | 7
|
18 | period-prevalence | 7
|
19 | squads | 7
|
20 | combirx | 6
|
21 | institute-designated | 6
|
22 | sub-cohorts | 4
|
23 | therapy-bone | 4
|
24 | therapy-head | 4
|
25 | 22791 | 3
|
26 | asylums | 3
|
27 | bearers | 3
|
28 | cytopathol | 3
|
29 | group-7 | 3
|
30 | patients/survivors | 3
|
31 | recurrence/relapse | 3
|
32 | res. | 3
|
33 | therapy-cervix | 3
|
34 | therapy-colorectal | 3
|
35 | therapy-hepatobiliary | 3
|
36 | therapy-ovarian | 3
|
37 | 'barke | 2
|
38 | 'unnecessary | 2
|
39 | 3-europe | 2
|
40 | 8452 | 2
|
41 | institute-common | 2
|
42 | mac15a | 2
|
43 | patients.there | 2
|
44 | pc3-m | 2
|
45 | polymarker | 2
|
46 | prevention/therapy | 2
|
47 | rvot-pacing | 2
|
48 | rvs162 | 2
|
49 | therapy-anaemia | 2
|
50 | therapy-brain | 2
|
51 | treatment-general | 2
|
52 | ulcerosa | 2
|
53 | ≤3cm | 2
|
54 | 'elimination | 1
|
55 | 'flashbacks | 1
|
56 | 0.022±0.002mg/min | 1
|
57 | 19.6/19.9 | 1
|
58 | 99:1757-62 | 1
|
59 | adolescents.ten | 1
|
60 | anorexiacachexia | 1
|
61 | bio-repository | 1
|
62 | bp-increasing | 1
|
63 | bronchoalveolar-type | 1
|
64 | cell-inherent | 1
|
65 | celllines | 1
|
66 | condoms.five | 1
|
67 | control/american | 1
|
68 | control/chemoprevention | 1
|
69 | daily.they | 1
|
70 | deaths/incidence | 1
|
71 | distingishes | 1
|
72 | duringpast | 1
|
73 | genetics–specific | 1
|
74 | group-1991 | 1
|
75 | group-2961 | 1
|
76 | hypofraction | 1
|
77 | initiation/progression | 1
|
78 | institute-prostate | 1
|
79 | institute/department | 1
|
80 | institute/hospital | 1
|
81 | institute/nih/dhhs | 1
|
82 | irroratus | 1
|
83 | journal-published | 1
|
84 | leg/stiffness | 1
|
85 | monique | 1
|
86 | nifct | 1
|
87 | o-glycopeptidome | 1
|
88 | opportunely | 1
|
89 | patients-such | 1
|
90 | patients.11 | 1
|
91 | patients.oncogene | 1
|
92 | patients.reserved | 1
|
93 | power.fig | 1
|
94 | progression/survival | 1
|
95 | rate.clinical | 1
|
96 | registry-identified | 1
|
97 | registry/questionnaires | 1
|
98 | related-death | 1
|
99 | resections/year | 1
|
100 | risk/gene | 1
|
101 | risk/prognosis | 1
|
102 | risk/syndrom | 1
|
103 | saline/blood | 1
|
104 | scale≥18 | 1
|
105 | sells | 1
|
106 | specific- | 1
|
107 | surivors | 1
|
108 | symptoms/response | 1
|
109 | therapy-anemia | 1
|
110 | therapy-anorexia | 1
|
111 | therapy-gastric | 1
|
112 | therapy-lymphoma | 1
|
113 | therapy-ovary | 1
|
114 | therapy.oncogene | 1
|
115 | treatment-breast | 1
|
116 | treatment-head | 1
|
117 | treatment-lung | 1
|
118 | treatment-medicinal | 1
|
119 | treatment.cellular | 1
|
120 | treatment.oncogene | 1
|
121 | treatment/research | 1
|
122 | tumorogenesis | 1
|
123 | units/centres | 1
|
124 | v7.0 | 1
|
125 | worries/distress | 1
|
Words in alphabetical order
1 | 'barke | 2
|
2 | 'elimination | 1
|
3 | 'flashbacks | 1
|
4 | 'unnecessary | 2
|
5 | 0.022±0.002mg/min | 1
|
6 | 19.6/19.9 | 1
|
7 | 22791 | 3
|
8 | 3-europe | 2
|
9 | 8452 | 2
|
10 | 99:1757-62 | 1
|
11 | adolescents.ten | 1
|
12 | anorexiacachexia | 1
|
13 | antigen-125 | 10
|
14 | asylums | 3
|
15 | bearers | 3
|
16 | bio-repository | 1
|
17 | bp-increasing | 1
|
18 | bronchoalveolar-type | 1
|
19 | cell-inherent | 1
|
20 | celllines | 1
|
21 | chemoprevention | 837
|
22 | combirx | 6
|
23 | condoms.five | 1
|
24 | control/american | 1
|
25 | control/chemoprevention | 1
|
26 | cytopathol | 3
|
27 | daily.they | 1
|
28 | deaths/incidence | 1
|
29 | defenders | 9
|
30 | distingishes | 1
|
31 | duringpast | 1
|
32 | epidemiol | 19
|
33 | genetics–specific | 1
|
34 | group-1991 | 1
|
35 | group-2961 | 1
|
36 | group-7 | 3
|
37 | hypofraction | 1
|
38 | initiation/progression | 1
|
39 | institute-common | 2
|
40 | institute-designated | 6
|
41 | institute-prostate | 1
|
42 | institute/department | 1
|
43 | institute/hospital | 1
|
44 | institute/nih/dhhs | 1
|
45 | irroratus | 1
|
46 | journal-published | 1
|
47 | leg/stiffness | 1
|
48 | mac15a | 2
|
49 | microspores | 19
|
50 | monique | 1
|
51 | nifct | 1
|
52 | non-withdrawers | 7
|
53 | o-glycopeptidome | 1
|
54 | opportunely | 1
|
55 | patients-such | 1
|
56 | patients.11 | 1
|
57 | patients.oncogene | 1
|
58 | patients.reserved | 1
|
59 | patients.there | 2
|
60 | patients/survivors | 3
|
61 | pc3-m | 2
|
62 | period-prevalence | 7
|
63 | perpetrators | 66
|
64 | polymarker | 2
|
65 | power.fig | 1
|
66 | prevention/therapy | 2
|
67 | progression/survival | 1
|
68 | rate.clinical | 1
|
69 | recidivists | 11
|
70 | recurrence/relapse | 3
|
71 | registry-identified | 1
|
72 | registry/questionnaires | 1
|
73 | related-death | 1
|
74 | res. | 3
|
75 | resections/year | 1
|
76 | risk/gene | 1
|
77 | risk/prognosis | 1
|
78 | risk/syndrom | 1
|
79 | rvot-pacing | 2
|
80 | rvs162 | 2
|
81 | saline/blood | 1
|
82 | scale≥18 | 1
|
83 | sells | 1
|
84 | specific- | 1
|
85 | squads | 7
|
86 | sub-cohorts | 4
|
87 | subpanel | 8
|
88 | sufferers | 327
|
89 | surivors | 1
|
90 | survivors | 4,217
|
91 | survivorship | 267
|
92 | symptoms/response | 1
|
93 | therapy-anaemia | 2
|
94 | therapy-anemia | 1
|
95 | therapy-anorexia | 1
|
96 | therapy-bone | 4
|
97 | therapy-brain | 2
|
98 | therapy-breast | 23
|
99 | therapy-cervix | 3
|
100 | therapy-colorectal | 3
|
101 | therapy-gastric | 1
|
102 | therapy-general | 33
|
103 | therapy-head | 4
|
104 | therapy-hepatobiliary | 3
|
105 | therapy-lung | 12
|
106 | therapy-lymphoma | 1
|
107 | therapy-ovarian | 3
|
108 | therapy-ovary | 1
|
109 | therapy-prostate | 11
|
110 | therapy.oncogene | 1
|
111 | treatment-breast | 1
|
112 | treatment-general | 2
|
113 | treatment-head | 1
|
114 | treatment-lung | 1
|
115 | treatment-medicinal | 1
|
116 | treatment.cellular | 1
|
117 | treatment.oncogene | 1
|
118 | treatment/research | 1
|
119 | tumorogenesis | 1
|
120 | ulcerosa | 2
|
121 | units/centres | 1
|
122 | v7.0 | 1
|
123 | victims | 653
|
124 | worries/distress | 1
|
125 | ≤3cm | 2
|
Words in suffix order
1 | specific- | 1
|
2 | res. | 3
|
3 | v7.0 | 1
|
4 | patients.11 | 1
|
5 | group-2961 | 1
|
6 | 22791 | 3
|
7 | group-1991 | 1
|
8 | 8452 | 2
|
9 | 99:1757-62 | 1
|
10 | rvs162 | 2
|
11 | antigen-125 | 10
|
12 | group-7 | 3
|
13 | scale≥18 | 1
|
14 | 19.6/19.9 | 1
|
15 | mac15a | 2
|
16 | therapy-anaemia | 2
|
17 | therapy-anemia | 1
|
18 | anorexiacachexia | 1
|
19 | therapy-anorexia | 1
|
20 | therapy-lymphoma | 1
|
21 | ulcerosa | 2
|
22 | genetics–specific | 1
|
23 | therapy-gastric | 1
|
24 | treatment-head | 1
|
25 | therapy-head | 4
|
26 | journal-published | 1
|
27 | registry-identified | 1
|
28 | institute-designated | 6
|
29 | patients.reserved | 1
|
30 | saline/blood | 1
|
31 | deaths/incidence | 1
|
32 | period-prevalence | 7
|
33 | 'barke | 2
|
34 | o-glycopeptidome | 1
|
35 | risk/gene | 1
|
36 | patients.oncogene | 1
|
37 | treatment.oncogene | 1
|
38 | therapy.oncogene | 1
|
39 | therapy-bone | 4
|
40 | 3-europe | 2
|
41 | bronchoalveolar-type | 1
|
42 | patients.there | 2
|
43 | symptoms/response | 1
|
44 | recurrence/relapse | 3
|
45 | institute-prostate | 1
|
46 | therapy-prostate | 11
|
47 | monique | 1
|
48 | condoms.five | 1
|
49 | power.fig | 1
|
50 | rvot-pacing | 2
|
51 | bp-increasing | 1
|
52 | treatment-lung | 1
|
53 | therapy-lung | 12
|
54 | treatment/research | 1
|
55 | patients-such | 1
|
56 | related-death | 1
|
57 | rate.clinical | 1
|
58 | treatment-medicinal | 1
|
59 | treatment-general | 2
|
60 | therapy-general | 33
|
61 | therapy-colorectal | 3
|
62 | institute/hospital | 1
|
63 | progression/survival | 1
|
64 | subpanel | 8
|
65 | cytopathol | 3
|
66 | epidemiol | 19
|
67 | pc3-m | 2
|
68 | ≤3cm | 2
|
69 | risk/syndrom | 1
|
70 | control/american | 1
|
71 | therapy-ovarian | 3
|
72 | adolescents.ten | 1
|
73 | therapy-brain | 2
|
74 | 0.022±0.002mg/min | 1
|
75 | initiation/progression | 1
|
76 | 'elimination | 1
|
77 | hypofraction | 1
|
78 | chemoprevention | 837
|
79 | control/chemoprevention | 1
|
80 | institute-common | 2
|
81 | survivorship | 267
|
82 | resections/year | 1
|
83 | treatment.cellular | 1
|
84 | polymarker | 2
|
85 | squads | 7
|
86 | distingishes | 1
|
87 | celllines | 1
|
88 | registry/questionnaires | 1
|
89 | microspores | 19
|
90 | units/centres | 1
|
91 | institute/nih/dhhs | 1
|
92 | tumorogenesis | 1
|
93 | risk/prognosis | 1
|
94 | 'flashbacks | 1
|
95 | sells | 1
|
96 | victims | 653
|
97 | asylums | 3
|
98 | defenders | 9
|
99 | bearers | 3
|
100 | sufferers | 327
|
101 | non-withdrawers | 7
|
102 | perpetrators | 66
|
103 | surivors | 1
|
104 | survivors | 4,217
|
105 | patients/survivors | 3
|
106 | leg/stiffness | 1
|
107 | worries/distress | 1
|
108 | sub-cohorts | 4
|
109 | recidivists | 11
|
110 | irroratus | 1
|
111 | nifct | 1
|
112 | institute/department | 1
|
113 | cell-inherent | 1
|
114 | treatment-breast | 1
|
115 | therapy-breast | 23
|
116 | duringpast | 1
|
117 | therapy-cervix | 3
|
118 | combirx | 6
|
119 | daily.they | 1
|
120 | opportunely | 1
|
121 | prevention/therapy | 2
|
122 | therapy-hepatobiliary | 3
|
123 | 'unnecessary | 2
|
124 | therapy-ovary | 1
|
125 | bio-repository | 1
|